Fan He-bin, Guo Ya-bing, Luo Kang-xian, Hou Jin-lin, Wang Zhan-hui, Zhang Ming-xia
Department of Infectious Diseases, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, China.
Zhonghua Gan Zang Bing Za Zhi. 2005 Jul;13(7):488-90.
To study the effects of genotypes of HBV and HBeAg on the response to PEG-interferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients.
PCR-RFLP and S gene sequencing were conducted in 42 CHB patients.
The sustained response (SR) rates were 66.7% in genotype B and 27.3% in genotype C group. The P value was 0.039 by the Pearson Chi-square test, while it was 0.06 by the Fisher's exact test. The results suggested a trend that patients with genotype B HBV compared to genotype C had better SR to PEG-IFN therapy, although the difference was not significant. Results also showed that SR rate in patients with HBeAg-negative CHB (7/8 87.5%) was significantly higher than that in HBe+ CHB patients (8/21 38.1%, P < 0.05).
Our results indicate that HBV genotype and HBeAg, especially the later, are main factors for predicting PEG-IFN therapy response in CHB patients.
研究慢性乙型肝炎（CHB）患者中HBV基因型和HBeAg对聚乙二醇干扰素α（PEG-IFN）治疗反应的影响。
对42例CHB患者进行PCR-RFLP和S基因测序。
B基因型组的持续应答（SR）率为66.7%，C基因型组为27.3%。经Pearson卡方检验，P值为0.039，经Fisher精确检验，P值为0.06。结果提示，B基因型HBV患者与C基因型患者相比，对PEG-IFN治疗的SR趋势较好，尽管差异不显著。结果还显示，HBeAg阴性CHB患者的SR率（7/8，87.5%）显著高于HBeAg阳性CHB患者（8/21，38.1%，P<0.05）。
我们的结果表明，HBV基因型和HBeAg，尤其是后者，是预测CHB患者PEG-IFN治疗反应的主要因素。
